Radiopharm Theranostics
Radiopharm Theranostics is a clinical-stage radiotherapeutics company focused on developing a pipeline of first-in-class radiopharmaceuticals for the diagnosis and treatment of cancer. The company aims to transform cancer care by delivering innovative solutions for earlier detection and personalized treatment of cancers with unmet needs.
Short position
Radiopharm Theranostics (ASX:RAD) has 1.27% of its shares on issue reported as short positions as of 16 Sept 2026, or about 54,932,710 shares. Over the past 30 days that figure has risen 1.25 percentage points, and over 90 days it has risen 1.22 percentage points. RAD is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Radiopharm Theranostics (RAD) short interest history
RAD Short Interest History
- 30-day change
- +1.25pp
- 90-day change
- +1.22pp
- 1-year change
- +1.24pp
- All-time high
- 1.27% (September 2026)
- All-time low
- 0.00% (September 2025)
Is RAD heavily shorted?
Not especially: 1.27% short interest is modest by ASX standards, ranking #217 of 799 ASX securities with reported short positions. ASIC requires positions of 0.01% of issued capital or $100,000 (whichever is less) to be reported.
How has RAD's short interest changed recently?
Over the past 30 days Radiopharm Theranostics's short interest has risen 1.25 percentage points, and over 90 days it has risen 1.22 percentage points. The current level is 1.27% of shares on issue.
What is the highest RAD's short interest has been?
Since 2011, Radiopharm Theranostics's short interest peaked at 1.27% in September 2026 and bottomed at 0.00% in September 2025.
Where does this data come from?
All figures are sourced from daily ASIC short position reports, published with a four trading-day (T+4) delay. Shorted aggregates the full history since 2011. See our methodology.